← Leaderboards
Erinn B Rankin
Stanford University
$3,755,975
Attributed
$3,755,975
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $849.8K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,755,975 · 4
By mechanism
R01$2,331,884 · 2
P01$1,424,091 · 2
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Calvin J Kuo$48,363,495
- George P Yang$108,000
- Maximilian Diehn$12,346,945
- Quynh-Thu X Le$15,492,013
- Donna M Peehl$4,923,077
Others in their field
Other Emerging Leaders on “Signal Transduction”
- Yunda Huang · Fred Hutchinson Cancer Center$53,064,276
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
- Leonard Freedman · Leidos Biomedical Research, Inc.$32,575,497
- Bala Raja · Luminostics, Inc.$28,624,460
- Suzanne L Baker · University Of Pittsburgh At Pittsburgh$20,465,582
Research focus
Signal TransductionResponseMalignant NeoplasmsTumorMolecularSafetyTherapeutic TargetRenal CarcinomaCellsTumor GrowthApoptosisPublic HealthCancer CellKnock-DownInsightMetabolomicsMapsMissionInnovationGlutamineMetabolicMetabolismModificationEpitranscriptomics
Grant awards (9)
The role of the RNA demethylase FTO in metabolic reprogramming of renal cell carcinoma$459,722
R01 · FY2025 · CA · contact PI
Project 4: FTO Inhibition to Enhance the Therapeutic Index of Radiotherapy$347,017
P01 · FY2025 · CA · contact PI
The role of the RNA demethylase FTO in metabolic reprogramming of renal cell carcinoma$436,355
R01 · FY2024 · CA · contact PI
Project 4: FTO Inhibition to Enhance the Therapeutic Index of Radiotherapy$342,972
P01 · FY2024 · CA · contact PI
The role of the RNA demethylase FTO in metabolic reprogramming of renal cell carcinoma$477,934
R01 · FY2023 · CA · contact PI
Project 4: FTO Inhibition to Enhance the Therapeutic Index of Radiotherapy$371,837
P01 · FY2023 · CA · contact PI
Project 4: FTO Inhibition to Enhance the Therapeutic Index of Radiotherapy$362,265
P01 · FY2022 · CA · contact PI
Preclinical Testing of a Novel Therapy Targeting AXL in Advanced Kidney Cancer$483,315
R01 · FY2020 · CA · contact PI
Preclinical Testing of a Novel Therapy Targeting AXL in Advanced Kidney Cancer$474,558
R01 · FY2019 · CA · contact PI